Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients.

Weenink B, van Brakel M, Wijers R, Sillevis Smitt PAE, French PJ, Debets R.

J Neurooncol. 2019 Aug;144(1):79-87. doi: 10.1007/s11060-019-03228-6. Epub 2019 Jun 25.

2.

The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies.

van Coevorden-Hameete MH, de Bruijn MAAM, de Graaff E, Bastiaansen DAEM, Schreurs MWJ, Demmers JAA, Ramberger M, Hulsenboom ESP, Nagtzaam MMP, Boukhrissi S, Veldink JH, Verschuuren JJGM, Hoogenraad CC, Sillevis Smitt PAE, Titulaer MJ.

Brain. 2019 Jun 1;142(6):1631-1643. doi: 10.1093/brain/awz094.

3.

Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis.

de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, van Donselaar CA, Majoie MHJM, Neuteboom RF, Sillevis Smitt PAE, Thijs RD, Titulaer MJ.

Neurology. 2019 May 7;92(19):e2185-e2196. doi: 10.1212/WNL.0000000000007475. Epub 2019 Apr 12.

4.

Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients.

Bechakra M, Moerdijk F, van Rosmalen J, Koch BCP, van der Rijt CCD, Sillevis Smitt PAE, Jongen JLM.

Eur J Cancer. 2018 Dec;105:79-87. doi: 10.1016/j.ejca.2018.09.036. Epub 2018 Nov 12.

PMID:
30439627
5.

Novel methods to diagnose leptomeningeal metastases in breast cancer.

Angus L, Martens JWM, van den Bent MJ, Sillevis Smitt PAE, Sleijfer S, Jager A.

Neuro Oncol. 2019 Mar 18;21(4):428-439. doi: 10.1093/neuonc/noy186.

PMID:
30418595
6.

Predictive value of electroencephalography in anti-NMDA receptor encephalitis.

Sonderen AV, Arends S, Tavy DLJ, Bastiaansen AEM, Bruijn MAAM, Schreurs MWJ, Sillevis Smitt PAE, Titulaer MJ.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1101-1106. doi: 10.1136/jnnp-2018-318376. Epub 2018 Aug 22.

PMID:
30135187
7.

IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.

Gao Y, de Wit M, Struys EA, van der Linde HCZ, Salomons GS, Lamfers MLM, Willemsen R, Sillevis Smitt PAE, French PJ.

PLoS One. 2018 Jun 28;13(6):e0199737. doi: 10.1371/journal.pone.0199737. eCollection 2018.

8.

Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis.

de Bruijn MAAM, Aarsen FK, van Oosterhout MP, van der Knoop MM, Catsman-Berrevoets CE, Schreurs MWJ, Bastiaansen DEM, Sillevis Smitt PAE, Neuteboom RF, Titulaer MJ; CHANCE Study Group.

Neurology. 2018 May 29;90(22):e1997-e2005. doi: 10.1212/WNL.0000000000005605. Epub 2018 Apr 27.

9.

Immune Repertoire after Immunization As Seen by Next-Generation Sequencing and Proteomics.

VanDuijn MM, Dekker LJ, van IJcken WFJ, Sillevis Smitt PAE, Luider TM.

Front Immunol. 2017 Oct 16;8:1286. doi: 10.3389/fimmu.2017.01286. eCollection 2017.

10.

Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes.

van Coevorden-Hameete MH, van Beuningen SFB, Perrenoud M, Will LM, Hulsenboom E, Demonet JF, Sabater L, Kros JM, Verschuuren JJGM, Titulaer MJ, de Graaff E, Sillevis Smitt PAE, Hoogenraad CC.

Ann Clin Transl Neurol. 2017 Jul 28;4(9):680-686. doi: 10.1002/acn3.396. eCollection 2017 Sep.

11.

Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.

Matic M, Jongen JL, Elens L, de Wildt SN, Tibboel D, Sillevis Smitt PA, van Schaik RH.

Pharmacogenomics. 2017 Aug;18(12):1133-1142. doi: 10.2217/pgs-2017-0060. Epub 2017 Jul 26.

PMID:
28745577
12.

Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4.

van Sonderen A, Roelen DL, Stoop JA, Verdijk RM, Haasnoot GW, Thijs RD, Wirtz PW, Schreurs MW, Claas FH, Sillevis Smitt PA, Titulaer MJ.

Ann Neurol. 2017 Feb;81(2):193-198. doi: 10.1002/ana.24858. Epub 2017 Jan 27.

PMID:
28026046
13.

The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.

Lilleker JB, Jones MS, Mohanraj R, Yeo T, Chai JY, Tan K, van Sonderen A, Schreurs MW, de Bruijn MA, Sillevis Smitt PA, Titulaer MJ.

Neurology. 2016 Oct 25;87(17):1848-1849. No abstract available.

PMID:
27777346
14.

Adherence to Analgesics in Oncology Outpatients: Focus on Taking Analgesics on Time.

Oldenmenger WH, Sillevis Smitt PAE, de Raaf PJ, van der Rijt CCD.

Pain Pract. 2017 Jun;17(5):616-624. doi: 10.1111/papr.12490. Epub 2016 Oct 14.

PMID:
27739244
15.

Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.

van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, van Coevorden-Hameete MH, Wirtz PW, Schreurs MW, Sillevis Smitt PA, Titulaer MJ.

Neurology. 2016 Oct 4;87(14):1449-1456. Epub 2016 Sep 2.

PMID:
27590293
16.

From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time.

van Sonderen A, Schreurs MW, Wirtz PW, Sillevis Smitt PA, Titulaer MJ.

Autoimmun Rev. 2016 Oct;15(10):970-4. doi: 10.1016/j.autrev.2016.07.018. Epub 2016 Jul 30. Review.

17.

The clinical spectrum of Caspr2 antibody-associated disease.

van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP, Lancaster E, Wirtz PW, Schreurs MW, Sillevis Smitt PA, Graus F, Dalmau J, Titulaer MJ.

Neurology. 2016 Aug 2;87(5):521-8. doi: 10.1212/WNL.0000000000002917. Epub 2016 Jul 1.

18.

Detection and Characterization of Autoantibodies to Neuronal Cell-Surface Antigens in the Central Nervous System.

van Coevorden-Hameete MH, Titulaer MJ, Schreurs MW, de Graaff E, Sillevis Smitt PA, Hoogenraad CC.

Front Mol Neurosci. 2016 May 31;9:37. doi: 10.3389/fnmol.2016.00037. eCollection 2016. Review.

19.

The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.

van Sonderen A, Schreurs MW, de Bruijn MA, Boukhrissi S, Nagtzaam MM, Hulsenboom ES, Enting RH, Thijs RD, Wirtz PW, Sillevis Smitt PA, Titulaer MJ.

Neurology. 2016 May 3;86(18):1692-9. doi: 10.1212/WNL.0000000000002637. Epub 2016 Apr 1.

PMID:
27037230
20.

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ.

Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13.

21.

Plasticity-related gene 5: A novel surface autoantigen in paraneoplastic cerebellar degeneration.

van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hulsenboom E, Sabater L, Hoogenraad CC, Sillevis Smitt PA.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e156. doi: 10.1212/NXI.0000000000000156. eCollection 2015 Oct. No abstract available.

22.

Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration.

Probst C, Komorowski L, de Graaff E, van Coevorden-Hameete M, Rogemond V, Honnorat J, Sabeter L, Graus F, Jarius S, Voltz R, Wildemann B, Franciotta D, Blöcker IM, Schlumberger W, Stöcker W, Sillevis Smitt PA.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e68. doi: 10.1212/NXI.0000000000000068. eCollection 2015 Apr.

23.

Pregnancy Zone Protein is Increased in the Alzheimer's Disease Brain and Associates with Senile Plaques.

Nijholt DA, Ijsselstijn L, van der Weiden MM, Zheng PP, Sillevis Smitt PA, Koudstaal PJ, Luider TM, Kros JM.

J Alzheimers Dis. 2015;46(1):227-38. doi: 10.3233/JAD-131628.

PMID:
25737043
24.

Tumor-specific mutations in low-frequency genes affect their functional properties.

Erdem-Eraslan L, Heijsman D, de Wit M, Kremer A, Sacchetti A, van der Spek PJ, Sillevis Smitt PA, French PJ.

J Neurooncol. 2015 May;122(3):461-70. doi: 10.1007/s11060-015-1741-1. Epub 2015 Feb 19.

25.

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

van den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, van Zwieten K, Prince J, van Duinen S, Sillevis Smitt PA, Taphoorn M, French PJ.

Neuro Oncol. 2015 Jul;17(7):935-41. doi: 10.1093/neuonc/nov013. Epub 2015 Feb 16.

26.

Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.

Taal W, van der Rijt CC, Dinjens WN, Sillevis Smitt PA, Wertenbroek AA, Bromberg JE, van Heuvel I, Kros JM, van den Bent MJ.

J Neurooncol. 2015 Jan;121(2):365-72. doi: 10.1007/s11060-014-1641-9. Epub 2014 Oct 26.

PMID:
25344884
27.

Circulating glioma biomarkers.

Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP.

Neuro Oncol. 2015 Mar;17(3):343-60. doi: 10.1093/neuonc/nou207. Epub 2014 Sep 24. Review.

28.

A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

de Jongste AH, van Gelder T, Bromberg JE, de Graaf MT, Gratama JW, Schreurs MW, Hooijkaas H, Sillevis Smitt PA.

Neuro Oncol. 2015 Jan;17(1):145-50. doi: 10.1093/neuonc/nou126. Epub 2014 Jul 3.

29.

Peptides from the variable region of specific antibodies are shared among lung cancer patients.

de Costa D, Broodman I, Calame W, Stingl C, Dekker LJ, Vernhout RM, de Koning HJ, Hoogsteden HC, Sillevis Smitt PA, van Klaveren RJ, Luider TM, Vanduijn MM.

PLoS One. 2014 May 1;9(5):e96029. doi: 10.1371/journal.pone.0096029. eCollection 2014.

30.

Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system.

van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PA.

Autoimmun Rev. 2014 Mar;13(3):299-312. doi: 10.1016/j.autrev.2013.10.016. Epub 2013 Nov 10. Review.

PMID:
24225076
31.

Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma.

Iorio R, Damato V, Mirabella M, Vita MG, Hulsenboom E, Plantone D, Bizzarro A, Del Grande A, Sillevis Smitt PA.

J Neuroimmunol. 2013 Oct 15;263(1-2):155-8. doi: 10.1016/j.jneuroim.2013.07.015. Epub 2013 Aug 3.

PMID:
23958353
32.

MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.

van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG, den Dunnen WF, Tijssen C, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T, French PJ.

Clin Cancer Res. 2013 Oct 1;19(19):5513-22. doi: 10.1158/1078-0432.CCR-13-1157. Epub 2013 Aug 15.

33.

Serum proteomics in amnestic mild cognitive impairment.

Ijsselstijn L, Papma JM, Dekker LJ, Calame W, Stingl C, Koudstaal PJ, Prins ND, Sillevis Smitt PA, Luider TM.

Proteomics. 2013 Aug;13(16):2526-33. doi: 10.1002/pmic.201200190. Epub 2013 Jul 19.

PMID:
23868823
34.

Psychiatric phenomena as initial manifestation of encephalitis by anti-NMDAR antibodies.

Maat P, de Graaff E, van Beveren NM, Hulsenboom E, Verdijk RM, Koorengevel K, van Duijn M, Hooijkaas H, Hoogenraad C, Sillevis Smitt PA.

Acta Neuropsychiatr. 2013 Jun;25(3):128-36. doi: 10.1111/acn.12013.

PMID:
25287466
35.

Molecular subtypes of glioma identified by genome-wide methylation profiling.

Kloosterhof NK, de Rooi JJ, Kros M, Eilers PH, Sillevis Smitt PA, van den Bent MJ, French PJ.

Genes Chromosomes Cancer. 2013 Jul;52(7):665-74. doi: 10.1002/gcc.22062. Epub 2013 Apr 30.

PMID:
23629961
36.

Comparative study of targeted and label-free mass spectrometry methods for protein quantification.

IJsselstijn L, Stoop MP, Stingl C, Sillevis Smitt PA, Luider TM, Dekker LJ.

J Proteome Res. 2013 Apr 5;12(4):2005-11. doi: 10.1021/pr301221f. Epub 2013 Mar 21.

PMID:
23464858
37.

Effector memory and late memory T cells accumulate in the blood of CMV-carrying individuals but not in their cerebrospinal fluid.

de Jongste AH, de Graaf MT, van den Broek PD, Kraan J, Sillevis Smitt PA, Gratama JW.

Cytometry B Clin Cytom. 2013 Jul-Aug;84(4):218-21. doi: 10.1002/cyto.b.21073. Epub 2013 Feb 7.

38.

Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PH, Idbaih A, Spliet WG, den Dunnen WF, Teepen JL, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T, van den Bent MJ, French PJ.

J Clin Oncol. 2013 Jan 20;31(3):328-36. doi: 10.1200/JCO.2012.44.1444. Epub 2012 Dec 26.

39.

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.

de Jongste AH, de Graaf MT, Martinuzzi E, van den Broek PD, Kraan J, Lamers CH, Mallone R, Gratama JW, Sillevis Smitt PA.

Neuro Oncol. 2012 Jul;14(7):841-8. doi: 10.1093/neuonc/nos118. Epub 2012 May 15.

40.

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.

Taal W, Segers-van Rijn JM, Kros JM, van Heuvel I, van der Rijt CC, Bromberg JE, Sillevis Smitt PA, van den Bent MJ.

J Neurooncol. 2012 May;108(1):195-200. doi: 10.1007/s11060-012-0832-5. Epub 2012 Mar 7.

41.

A proteome comparison between physiological angiogenesis and angiogenesis in glioblastoma.

Mustafa DA, Dekker LJ, Stingl C, Kremer A, Stoop M, Sillevis Smitt PA, Kros JM, Luider TM.

Mol Cell Proteomics. 2012 Jun;11(6):M111.008466. doi: 10.1074/mcp.M111.008466. Epub 2012 Jan 25.

42.

Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material.

Gravendeel LA, de Rooi JJ, Eilers PH, van den Bent MJ, Sillevis Smitt PA, French PJ.

Br J Cancer. 2012 Jan 31;106(3):538-45. doi: 10.1038/bjc.2011.547. Epub 2011 Dec 20.

43.

A combined pain consultation and pain education program decreases average and current pain and decreases interference in daily life by pain in oncology outpatients: a randomized controlled trial.

Oldenmenger WH, Sillevis Smitt PA, van Montfort CA, de Raaf PJ, van der Rijt CC.

Pain. 2011 Nov;152(11):2632-9. doi: 10.1016/j.pain.2011.08.009. Epub 2011 Sep 8.

PMID:
21906879
44.

Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease.

Ijsselstijn L, Dekker LJ, Stingl C, van der Weiden MM, Hofman A, Kros JM, Koudstaal PJ, Sillevis Smitt PA, Ikram MA, Breteler MM, Luider TM.

J Proteome Res. 2011 Nov 4;10(11):4902-10. doi: 10.1021/pr200270z. Epub 2011 Sep 28.

PMID:
21879768
45.

Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas.

Bralten LB, Nouwens S, Kockx C, Erdem L, Hoogenraad CC, Kros JM, Moorhouse MJ, Sillevis Smitt PA, van der Spek P, van Ijcken W, Stubbs A, French PJ.

PLoS One. 2011;6(7):e22000. doi: 10.1371/journal.pone.0022000. Epub 2011 Jul 7.

46.

Flow cytometric characterization of cerebrospinal fluid cells.

de Graaf MT, de Jongste AH, Kraan J, Boonstra JG, Sillevis Smitt PA, Gratama JW.

Cytometry B Clin Cytom. 2011 Sep;80(5):271-81. doi: 10.1002/cyto.b.20603. Epub 2011 May 12. Review.

47.

Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells.

van den Hengel SK, de Vrij J, Uil TG, Lamfers ML, Sillevis Smitt PA, Hoeben RC.

Virol J. 2011 Apr 11;8:162. doi: 10.1186/1743-422X-8-162.

48.

Addition of serum-containing medium to cerebrospinal fluid prevents cellular loss over time.

de Graaf MT, van den Broek PD, Kraan J, Luitwieler RL, van den Bent MJ, Boonstra JG, Schmitz PI, Gratama JW, Sillevis Smitt PA.

J Neurol. 2011 Aug;258(8):1507-12. doi: 10.1007/s00415-011-5970-8. Epub 2011 Mar 12.

49.

Serum clusterin levels are not increased in presymptomatic Alzheimer's disease.

IJsselstijn L, Dekker LJ, Koudstaal PJ, Hofman A, Sillevis Smitt PA, Breteler MM, Luider TM.

J Proteome Res. 2011 Apr 1;10(4):2006-10. doi: 10.1021/pr101221h. Epub 2011 Feb 22.

PMID:
21280673
50.

Label-free peptide profiling of Orbitrap™ full mass spectra.

Titulaer MK, de Costa D, Stingl C, Dekker LJ, Sillevis Smitt PA, Luider TM.

BMC Res Notes. 2011 Jan 27;4:21. doi: 10.1186/1756-0500-4-21.

Supplemental Content

Loading ...
Support Center